Targeting TRAIL in the treatment of cancer: new developments

Bibliography

• Halliwell B. A super way to kill cancer cells? Nat Med 2000;6(10):1105-6
   PubMed Web of Science ®Google Scholar
• Kerr J, Winterford C, Harmon B. Apoptosis. Its significance in cancer and cancer Therapy. Cancer 1994;73(8):2013-26
   PubMed Web of Science ®Google Scholar
• Cheng E, Wei M, Weiler S, et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX-and BAK-mediated mitochondrial apoptosis. Mol Cell 2001;8(3):705-11
   PubMed Web of Science ®Google Scholar
• Zhang X, Tang N, Hadden TJ, Rishi AK. Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta 2011;1813(11):1978-86
   PubMed Web of Science ®Google Scholar
• Oda E, Ohki R, Murasawa H, et al. Noxa, a BH3-Only Member of the Bcl-2 Family and Candidate Mediator of p53-Induced Apoptosis. Science 2000;288(5468):1053-8
   PubMed Web of Science ®Google Scholar
• Ricci S, Jin Z, Dews M, et al. Direct Repression of FLIP Expression by c-myc Is a Major Determinant of TRAIL Sensitivity. Mol Cell Biol 2004;24(19):8541-55
   PubMed Web of Science ®Google Scholar
• Jost PJ, Grabow S, Gray D, et al. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 2009;460(7258):1035-9
   PubMed Web of Science ®Google Scholar
• Wilson NS, Yang A, Yang B, et al. Proapoptotic activation of death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor growth. Cancer Cell 2012;22(1):80-90
   PubMed Web of Science ®Google Scholar
• Sessler T, Healy S, Samali A, Szegezdi E. Structural determinants of DISC function: New insights into death receptor-mediated apoptosis signalling. Pharmacol Ther 2013;140(2):186-99
   PubMed Web of Science ®Google Scholar
• Barnhart B, Alappat E, Peter M. The CD95 type I/type II model. Semin Immunol 2003;15(3):185-93
   PubMed Web of Science ®Google Scholar
• Pitti R, Marsters S, Ruppert S, et al. Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family. J Biol Chem 1996;271(22):12687-90
   PubMed Web of Science ®Google Scholar
• Kops GJ, Medema RH, Glassford J, et al. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol 2002;22(7):2025-36
   PubMed Web of Science ®Google Scholar
• Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277(5327):818-21
   PubMed Web of Science ®Google Scholar
• Pan G, O’Rourke K, Chinnaiyan A, et al. The Receptor for the Cytotoxic Ligand TRAIL. Science 1997;276(5309):111-13
   PubMed Web of Science ®Google Scholar
• Mérino D, Lalaoui N, Morizot A, et al. Differential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2. Mol Cell Biol 2006;26(19):7046-55
   PubMed Web of Science ®Google Scholar
• Blair JM, Zhou H, Seibel MJ, Dunstan CR. Mechanisms of Disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat Rev Clin Oncol 2006;3(1):41-9
   Web of Science ®Google Scholar
• Ozoren N, El-Deiry WS. Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia 2002;4(6):551-7
   PubMed Web of Science ®Google Scholar
• Roy S, Nicholson DW. Cross-Talk in Cell Death Signaling. J Exp Med 2000;192(8):21-6
   PubMed Web of Science ®Google Scholar
• Steinhart L, Belz K, Fulda S. Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis. Cell Death Disease 2013;4(9):e802
   PubMedGoogle Scholar
• Song JH, Tse MC, Bellail A, et al. Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. Cancer Res 2007;67(14):6946-55
   PubMed Web of Science ®Google Scholar
• Galligan L, Longley DB, McEwan M, et al. Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol Cancer Ther 2005;4(12):2026-36
   PubMed Web of Science ®Google Scholar
• Roue G, Perez-Galan P, Lopez-Guerra M, et al. Selective inhibition of IkappaB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level. J Immunol 2007;178(3):1923-30
   PubMed Web of Science ®Google Scholar
• Duiker EW, Meijer A, van der Bilt AR, et al. Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis. Br J Cancer 2011;104(8):1278-87
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999;11(2):255-60
   PubMed Web of Science ®Google Scholar
• LaCasse E, Baird S, Korneluk R, MacKenzie A. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998;17(25):3247-59
   PubMed Web of Science ®Google Scholar
• Allensworth J, Aird K, Aldrich A, et al.P inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells. Mol Cancer Ther 2012;11(7):1518-27
   PubMed Web of Science ®Google Scholar
• Plastaras JP, Dorsey JF, Carroll K, et al. Role of PI3K/Akt signaling in TRAIL- and radiation-induced gastrointestinal apoptosis. Cancer Biol Ther 2008;7(12):2047-53
   PubMed Web of Science ®Google Scholar
• Zhang X, Borrow J, Zhang X, et al. Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene 2003;22(19):2869-81
   PubMed Web of Science ®Google Scholar
• Braeuer S, Buneker C, Mohr A, Zwacka R. Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells. Mol Cancer Res 2006;4(10):715-28
   PubMed Web of Science ®Google Scholar
• Watanabe N, Niitsu Y, Neda H, et al. [Antitumor effect of the tumor necrosis factor against various types of human cancer cells]. Gan To Kagaku Ryoho 1985;12(11):2185-9
   PubMedGoogle Scholar
• Urban JL, Shepard HM, Rothstein JL, et al. Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. Proc Natl Acad Sci U S A 1986;83(14):5233-7
   PubMed Web of Science ®Google Scholar
• Kimura K, Taguchi T, Urushizaki I, et al. Phase I study of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 1987;20(3):223-9
   PubMed Web of Science ®Google Scholar
• Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993;364(6440):806-9
   PubMed Web of Science ®Google Scholar
• Eisele G, Roth P, Hasenbach K, et al. APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro Oncol 2011;13(2):155-64
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999 104(2):155-62.1999
   Google Scholar
• Subbiah V, Brown RE, Buryanek J, et al. Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist. Mol Cancer Ther 2012;11(11):2541-6
   PubMed Web of Science ®Google Scholar
• Fang F, Wang AP, Yang SF. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand. Acta Pharmacol Sin 2005 26(11):1373-81.2005
   Web of Science ®Google Scholar
• Geng C, Hou J, Zhao Y, et al. A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma. Am J Hematol 2014;89(11):1037-42
   PubMed Web of Science ®Google Scholar
• Duiker EW, de Vries EG, Mahalingam D, et al. Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model. Clin Cancer Res 2009;15(6):2048-57
   PubMed Web of Science ®Google Scholar
• Allen JE, Ferrini R, Dicker DT, et al. Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes. Mol Cancer Ther 2012;11(10):2087-95
   PubMed Web of Science ®Google Scholar
• Wilson NS, Yang B, Yang A, et al. An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 2011;19(1):101-13
   PubMed Web of Science ®Google Scholar
• Pan Y, Haddad V, Sabin T, et al. Predictive value of Fc gamma receptor IIIa genotype in response to conatumumab in three phase II studies. J Clin Oncol 2011;29(15S):3103
   PubMedGoogle Scholar
• Lee BS, Kang SU, Hwang HS, et al. An agonistic antibody to human death receptor 4 induces apoptotic cell death in head and neck cancer cells through mitochondrial ROS generation. Cancer Lett 2012;322(1):45-57
   PubMed Web of Science ®Google Scholar
• Mom CH, Verweij J, Oldenhuis CN, et al. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res 2009;15(17):5584-90
   PubMed Web of Science ®Google Scholar
• den Hollander MW, Gietema JA, de Jong S, et al. Translating TRAIL-receptor targeting agents to the clinic. Cancer Lett 2013;332(2):194-201
   PubMed Web of Science ®Google Scholar
• Micheau O, Shirley S, Dufour F. Death receptors as targets in cancer. Br J Pharmacol 2013;169(8):1723-44
   PubMed Web of Science ®Google Scholar
• Wang G, Wang X, Yu H, et al. Small-molecule activation of the TRAIL receptor DR5 in human cancer cells. Nat Chem Biol 2012;9:84-9
   PubMed Web of Science ®Google Scholar
• Allen J, Krigsfeld G, Mayes P, et al. Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects. Sci Transl Med 2013;5(171):171ra17
   PubMed Web of Science ®Google Scholar
• Li B, Russell SJ, Compaan DM, et al. Activation of the proapoptotic death receptor DR5 by oligomeric peptide and antibody agonists. J Mol Biol 2006;361(3):522-36
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang B. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res 2008;6(12):1861-71
   PubMed Web of Science ®Google Scholar
• Jin Z, Dicker DT, El-Deiry WS. Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle 2002;1(1):82-9
   PubMed Web of Science ®Google Scholar
• Fuke H, Shiraki K, Sugimoto K. Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 2007;363(3):738-44
   PubMed Web of Science ®Google Scholar
• Garimella SV, Rocca A, Lipkowitz S. WEE1 Inhibition Sensitizes Basal Breast Cancer Cells to TRAIL-Induced Apoptosis. Mol Cancer Res 2012;10(1):75-85
   PubMed Web of Science ®Google Scholar
• Dolloff N, Mayes P, Hart L, et al. Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. Sci Transl Med 2011;3(86):86ra50
   PubMed Web of Science ®Google Scholar
• Arafa E, Zhu Q, Barakat B, et al. Tangeretin Sensitizes Cisplatin-resistant Human Ovarian Cancer Cells through Down-regulation of PI3K/Akt Signaling Pathway. Cancer Res 2009;69(23):8910-17
   PubMed Web of Science ®Google Scholar
• Siegelin MD, Gaiser T, Siegelin Y. The XIAP inhibitor Embelin enhances TRAIL-mediated apoptosis in malignant glioma cells by down-regulation of the short isoform of FLIP. Neurochem Int 2009;55(6):423-30
   PubMed Web of Science ®Google Scholar
• Gallant JN, Allen JE, Smith CD, et al. Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biol Ther 2011;12(3):239-51
   PubMed Web of Science ®Google Scholar
• Khanbolooki S, Nawrocki ST, Arumugam T, et al. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther 2006;5(9):2251-60
   PubMed Web of Science ®Google Scholar
• Yang Y-I, Lee K-T, Park H-J, et al. Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway. Carcinogenesis 2012;33(12):2488-98
   PubMed Web of Science ®Google Scholar
• Krystal GW. Teaching an old drug new tricks: Actinomycin D synergistically enhances sensitivity to the Bcl-2 antagonist ABT-737. Cancer Biol Ther 2010;10(9):930-2
   PubMed Web of Science ®Google Scholar
• Skommer J, Wlodkowic D, Matto M. HA14-1, a small molecule Bcl-2 antagonist, induces apoptosis and modulates action of selected anticancer drugs in follicular lymphoma B cells. Leuk Res 2006;30(3):322-31
   PubMed Web of Science ®Google Scholar
• Djavaheri-Mergny M, Maiuri MC, Kroemer G. Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1. Oncogene 2010;29(12):1717-19
   PubMed Web of Science ®Google Scholar
• Heidari N, Hicks MA, Harada H. GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy. Cell Death Dis 2010;1:e76
   PubMed Web of Science ®Google Scholar
• L Vidal RD, Dees EC, Chia S. A phase Ib study of LCL161, an oral inhibitor of apoptosis (IAP) antagonist, in combination with weekly paclitaxel in patients with advanced solid tumors. Cancer Res 2012;72:24, Suppl 3
   Google Scholar
• Safa AR, Pollok KE. Targeting the Anti-Apoptotic Protein c-FLIP for Cancer Therapy. Cancers (Basel) 2011;3(2):1639-71
   PubMedGoogle Scholar
• Meng RD, McDonald ERIII, Sheikh M. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Mol Ther 2000;1(2):130-44
   PubMed Web of Science ®Google Scholar
• Wainberg ZA, Messersmith WA, Peddi PF, et al. A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2013;12(4):248-54
   PubMed Web of Science ®Google Scholar
• Asakuma J, Sumitomo M, Asano T, Hayakawa M. Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. Cancer Res 2003;63(6):1365-70
   PubMed Web of Science ®Google Scholar
• Keating J, Tsoli M, Hallahan A, et al. Targeting the Inhibitor of Apoptosis Proteins as a Novel Therapeutic Strategy in Medulloblastoma. Mol Cancer Ther 2012;11(10):1-10
   Google Scholar
• Fay F, McLaughlin KM, Small DM, et al. Conatumumab (AMG 655) coated nanoparticles for targeted pro-apoptotic drug delivery. Biomaterials 2011;32(33):8645-53
   PubMed Web of Science ®Google Scholar
• Ding B, Wu X, Fan W, et al. Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity. Int J Nanomedicine 2011;6:1991-2005
   PubMed Web of Science ®Google Scholar
• Kim H, Jeong D, Kang HE, et al. A sulfate polysaccharide/TNF-related apoptosis-inducing ligand (TRAIL) complex for the long-term delivery of TRAIL in poly(lactic-co-glycolic acid) (PLGA) microspheres. J Pharm Pharmacol 2013;65(1):11-21
   PubMed Web of Science ®Google Scholar
• Cho M-H, Lee E-J, Son M, et al. A magnetic switch for the control of cell death signaling in in vitro and in vivo systems. Nat Mater 2012;11(12):1038-43
   PubMed Web of Science ®Google Scholar
• Stern HM, Padilla M, Wagner K, et al. Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab. Clin Cancer Res 2010;16(5):1587-96
   PubMed Web of Science ®Google Scholar
• de Haas EC, di Pietro A, Simpson KL, et al. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia 2008;10(10):1041-8
   PubMed Web of Science ®Google Scholar
• Belada D, Mayer J, Czuczman S. Phase II study of dulanermin plus rituximab in patients with relapsed follicular non-Hodgkin’s lymphoma (NHL). -- Belada et al. 28 (15): 8104 -- ASCO Meeting Abstracts. J Clin Oncol 2010;28(15S):8104
   Google Scholar
• Soria JC, Mark Z, Zatloukal P, et al. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol 2011;29(33):4442-51
   PubMed Web of Science ®Google Scholar
• Soria J, Smit E, Khayat D. Phase Ib study of dulanermin(recombinant human Apo2L/TRAIL) in combination with paclitaxel,carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 2010;28(9):1527-33
   PubMed Web of Science ®Google Scholar
• Yee L, Burrs A, Kozloff M. Phase Ib study of recombinant human Apo2L/TRAIL plus irinotecan and cetuximab or FOLFIRI in metastatic colorectal cancer (mCRC) patients (pts): Preliminary results – Yee et al. 27 (15): 4129 – ASCO Meeting Abstracts. J Clin Oncol 2009;27(15S):4129
   Google Scholar
• Wainberg ZA, Messersmith WA, Peddi PF, et al. A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2013;12(4):248-54
   PubMed Web of Science ®Google Scholar
• Greco FA, Bonomi P, Crawford J, et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 2008;61(1):82-90
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer - Full Text View - ClinicalTrials.gov. 2014
   Google Scholar
• Younes A, Vose JM, Zelenetz AD, et al. A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin’s lymphoma. Br J Cancer 2010;103(12):1783-7
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma - Full Text View - ClinicalTrials.gov. 2014
   Google Scholar
• Von Pawel J, Harvey H, Spigel D, et al. A randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC. J Clin Oncol 2010(18S):abstract LBA7501
   Google Scholar
• Sun W, Nelson D, Alberts S, et al. Phase Ib study of mapatumumab in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) and chronic viral hepatitis. J Clin Oncol 2011(Suppl 4):abstract 261
   Google Scholar
• ClinicalTrials.gov. A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g) - Full Text View - ClinicalTrials.gov. 2014
   Google Scholar
• ClinicalTrials.gov. A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g). 2014
   Google Scholar
• ClinicalTrials.gov. A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g). 2014
   Google Scholar
• ClinicalTrials.gov. A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g). 2014
   Google Scholar
• A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin’s Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g). 2014
   Google Scholar
• Paz-Ares L, Balint B, de Boer RH, et al. A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 2013;8(3):329-37
   PubMed Web of Science ®Google Scholar
• Kindler HL, Richards DA, Garbo LE, et al. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol 2012;23(11):2834-42
   PubMed Web of Science ®Google Scholar
• Demetri GD, Le Cesne A, Chawla SP, et al. First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study. Eur J Cancer 2012;48(4):547-63
   PubMed Web of Science ®Google Scholar
• Peeters M, Infante J, Rougier P, et al. Phase Ib/II trial of conatumumab and panitumumab (pmab) for the treatment (tx) of metastatic colorectal cancer (mCRC): Safety and efficacy. 2010 GI cancer symposium meeting proceedings, ASCO Chicago, June 1, 2010
   Google Scholar
• Cohn AL, Tabernero J, Maurel J, et al. A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. Ann Oncol 2013;24(7):1777-85
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer. 2014
   Google Scholar
• ClinicalTrials.gov. CS1008 - in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer. 2014
   Google Scholar
• Forero-Torres A, Infante JR, Waterhouse D, et al. Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy naive patients with unresectable or metastatic pancreatic cancer. Cancer Med 2013;2(6):925-32
   Google Scholar
• Reck M, Krzakowski M, Chmielowska E. A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naive metastatic/unresectable non-small cell lung cancer. Lung Cancer 2013;82(3):441-8
   PubMed Web of Science ®Google Scholar